These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11229270)

  • 1. Some unusual and severe forms of adverse drug reactions: a call for setting adverse drug reaction monitoring centres.
    Bhattacharya SK; Singh NK; Prasad RC; Sinha PR
    J Assoc Physicians India; 1998 Aug; 46(8):675-7. PubMed ID: 11229270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe cutaneous adverse reactions to drugs.
    Chia FL; Leong KP
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China.
    Li LF; Ma C
    Clin Exp Dermatol; 2006 Sep; 31(5):642-7. PubMed ID: 16901302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome).
    Guillaume JC; Roujeau JC; Revuz J; Penso D; Touraine R
    Arch Dermatol; 1987 Sep; 123(9):1166-70. PubMed ID: 3632001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
    Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe adverse cutaneous reactions to drugs.
    Roujeau JC; Stern RS
    N Engl J Med; 1994 Nov; 331(19):1272-85. PubMed ID: 7794310
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh, India.
    Sharma VK; Sethuraman G; Kumar B
    J Postgrad Med; 2001; 47(2):95-9. PubMed ID: 11832597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants.
    Wolkenstein P; Charue D; Laurent P; Revuz J; Roujeau JC; Bagot M
    Arch Dermatol; 1995 May; 131(5):544-51. PubMed ID: 7741540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blistering drug reactions].
    Roujeau JC
    Rev Prat; 2000 Jun; 50(12):1320-3. PubMed ID: 10972073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective analysis of adverse cutaneous drug reactions in patients hospitalized in Department of Dermatology and Venereology of Pomeranian Medical University in 1996-2006].
    Kacalak-Rzepka A; Klimowicz A; Bielecka-Grzela S; Załuga E; Maleszka R; Fabiańczyk H
    Ann Acad Med Stetin; 2008; 54(2):52-8. PubMed ID: 19374232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Life-threatening acute adverse cutaneous drug reactions.
    Wolf R; Orion E; Marcos B; Matz H
    Clin Dermatol; 2005; 23(2):171-81. PubMed ID: 15802211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cutaneous reactions to drugs].
    Mulder WM; Meinardi MM; Bruynzeel DP
    Ned Tijdschr Geneeskd; 2004 Feb; 148(9):415-20. PubMed ID: 15038200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study.
    Lin MS; Dai YS; Pwu RF; Chen YH; Chang NC
    Intern Med J; 2005 Mar; 35(3):188-90. PubMed ID: 15737140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic epidermal necrolysis/Stevens-Johnson syndrome: current trends in management.
    Dalli RL; Kumar R; Kennedy P; Maitz P; Lee S; Johnson R
    ANZ J Surg; 2007 Aug; 77(8):671-6. PubMed ID: 17635282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reactions to fluoroquinolones at a tertiary care hospital in northern India.
    Uppal R; Jhaj R; Malhotra S
    J Assoc Physicians India; 1998 Nov; 46(11):946-7. PubMed ID: 11229222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome.
    Ghislain PD; Roujeau JC
    Dermatol Online J; 2002 Jun; 8(1):5. PubMed ID: 12165215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse drug reactions among hospitalized elderly patients. Prospective study].
    González-Martín G; Yáñez L; Valenzuela E
    Rev Med Chil; 1997 Oct; 125(10):1129-36. PubMed ID: 9609030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.
    Mockenhaupt M; Kelly JP; Kaufman D; Stern RS;
    J Rheumatol; 2003 Oct; 30(10):2234-40. PubMed ID: 14528522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.